antitrombin iii defitsiti da trombotik holatni korreksiyalash

PPTX 15 стр. 277,6 КБ Бесплатная загрузка

15 стр.

FaylHub.uz

Скачать через Telegram

Размер 277,6 КБ

Тип файла PPTX

Страницы 15

Обновлено Дек 2025

Предварительный просмотр (5 стр.)

Прокрутите вниз 👇

1 / 15

powerpoint presentation antitrombin ||| defitsiti da trombotik holatni korreksiyalash qushoqova gulhayo bahodir qizi 1. pathophysiology of thrombosis in atiii deficiency 2. treatment and management of atiii deficiency in thrombotic states 3. antitrombin iii: physiology and deficiency plan: management of complications management of bleeding complications in atiii deficient patients often involves the administration of fresh frozen plasma (ffp) at a rate of 10-15 ml/kg to achieve a rapid increase in atiii activity levels, followed by close monitoring of coagulation parameters. heparin-induced thrombocytopenia (hit) is a serious complication, especially if patients are receiving heparin therapy. careful monitoring of platelet counts is crucial, with a decrease of >50% from baseline suggesting hit. in cases of severe thrombotic events despite atiii replacement therapy, additional treatment may include direct thrombin inhibitors or factor xa inhibitors, requiring careful titration and close monitoring for bleeding risk and efficacy, potentially involving inr and aptt assessments. conclusion and future …

2 / 15

otic events (dvt, pe) reduction, through imaging (e.g., ultrasound) or clinical symptom improvement (reduced leg swelling, chest pain), is critical for evaluating treatment success; a reduction of 50% in event risk is a common goal. monitoring antithrombin iii (atiii) levels using chromogenic assays or elisa is crucial; target therapeutic levels are typically 80-120% of normal, and frequent monitoring (e.g., 2-3 times weekly initially) is needed to optimize dosing and efficacy. assessment of coagulation parameters, including pt, aptt, and thrombin time, provides indirect evidence of atiii therapy effectiveness, showing improvement in clotting times. significant deviations from established ranges warrant immediate attention. antitrombin iii concentrate: types and administration while rapid administration is sometimes needed in acute thrombotic events, the infusion rate for atiii concentrates is typically controlled to minimize adverse reactions; rates may range from 2 to 5 ml/min, adjusted according to patient response and clinical guidelines. administration routes for atiii concentrate …

3 / 15

rely deficient newborns, emphasizing the critical role of atiii in early life. approximately 50% of individuals with inherited atiii deficiency experience thrombotic events before the age of 50, highlighting the substantial risk of early-onset venous thromboembolism (vte) in this population. diagnosis of antitrombin iii deficiency antitrombin iii activity levels are typically measured using chromogenic assays, which quantify the inhibition of thrombin activity; levels below 70% of normal are generally considered deficient. genetic testing, identifying mutations in the serpinc1 gene, is crucial for confirming diagnosis and guiding family screening, particularly in cases with atypical or discordant functional assay results. functional assays, measuring the rate of thrombin inhibition, are preferred over antigenic assays which measure protein amount, as they reveal the actual functional deficit responsible for thrombotic risk. introduction to antitrombin iii antitrombin iii (atiii) is a serine protease inhibitor, a key component of the natural anticoagulant system, neutralizing approximately 70-80% of …

4 / 15

nd factors ixa, xa, xia, and xiia with a second-order rate constant of approximately 10⁷ m⁻¹s⁻¹. atiii's anticoagulant function is significantly enhanced by heparin, a glycosaminoglycan, which accelerates its binding to target proteases by approximately 1000-fold, thereby increasing its inhibitory activity. treatment strategies for atiii deficiency recombinant atiii (ratiii) offers an alternative, providing a consistent and virus-inactivated product; however, it's often more costly than plasma-derived atiii and may require higher dosages (potentially 100 units/kg or more) depending on the patient's needs. prophylactic atiii therapy, typically involving regular infusions of concentrates at intervals determined by monitoring of atiii levels (e.g., weekly or bi-weekly), is crucial for patients with severe atiii deficiency (less than 20% of normal levels) to prevent recurrent thrombotic events. treatment for atiii deficiency involves plasma-derived atiii concentrates, administered intravenously at doses tailored to the individual's deficiency severity (e.g., 60-80 units/kg) to achieve therapeutic levels and prevent further thrombosis. …

5 / 15

or reduced levels of atiii impair the natural anticoagulant pathways, specifically the inhibition of factor xa and thrombin, thereby disrupting the delicate balance between coagulation and fibrinolysis. thrombosis in atiii deficiency manifests as venous thromboembolism (vte), including deep vein thrombosis (dvt) and pulmonary embolism (pe), due to the hypercoagulable state resulting from inadequate thrombin inhibition. atiii deficiency leads to uncontrolled thrombin activity, increasing the risk of thrombosis by 5-10 fold. this is because atiii normally neutralizes approximately 70% of thrombin generated during coagulation. antitrombin iii deficiency: types and genetics over 100 different mutations in the serpinc1 gene, which encodes for atiii, have been identified, highlighting the genetic heterogeneity of this deficiency and contributing to the diverse clinical presentations observed in affected individuals. antitrombin iii deficiency is inherited in an autosomal dominant pattern in approximately 85% of cases, meaning only one copy of a mutated gene is sufficient to cause the …

Хотите читать дальше?

Скачайте все 15 страниц бесплатно через Telegram.

Скачать полный файл

О "antitrombin iii defitsiti da trombotik holatni korreksiyalash"

powerpoint presentation antitrombin ||| defitsiti da trombotik holatni korreksiyalash qushoqova gulhayo bahodir qizi 1. pathophysiology of thrombosis in atiii deficiency 2. treatment and management of atiii deficiency in thrombotic states 3. antitrombin iii: physiology and deficiency plan: management of complications management of bleeding complications in atiii deficient patients often involves the administration of fresh frozen plasma (ffp) at a rate of 10-15 ml/kg to achieve a rapid increase in atiii activity levels, followed by close monitoring of coagulation parameters. heparin-induced thrombocytopenia (hit) is a serious complication, especially if patients are receiving heparin therapy. careful monitoring of platelet counts is crucial, with a decrease of >50% from baseline suggesting...

Этот файл содержит 15 стр. в формате PPTX (277,6 КБ). Чтобы скачать "antitrombin iii defitsiti da trombotik holatni korreksiyalash", нажмите кнопку Telegram слева.

Теги: antitrombin iii defitsiti da tr… PPTX 15 стр. Бесплатная загрузка Telegram